All Stories

  1. Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients

    Article • Expert Review of Gastroenterology & Hepatology, August 2019, Taylor & Francis

    Shereen Abdel Alem, Aisha Elsharkawy , Yehia El Shazly, Mohamed El Kassas, dina ziada

  2. DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV

    Article • Expert Review of Gastroenterology & Hepatology, May 2019, Taylor & Francis

    Dr Heba Omar, Shereen Abdel Alem, Aisha Elsharkawy , Dr Walid Kamal Ibrahim

  3. Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon

    Article • Journal of Gastroenterology and Hepatology, August 2017, Wiley

    Aisha Elsharkawy , Shereen Abdel Alem

  4. Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience

    Article • Journal of Medical Virology, August 2017, Wiley

    Aisha Elsharkawy , Shereen Abdel Alem

  5. HCV in EGYPT

    Article • Hepatic Medicine Evidence and Research, July 2017, Dove Medical Press

    Aisha Elsharkawy , Mohamed El Kassas

  6. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients

    Article • Expert Review of Gastroenterology & Hepatology, May 2017, Taylor & Francis

    Aisha Elsharkawy

  7. Hepatitis C infection in Egypt: prevalence, impact and management strategies

    Article • Hepatic Medicine Evidence and Research, May 2017, Dove Medical Press

    Aisha Elsharkawy , Mohamed El Kassas

  8. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt

    Article • Alimentary Pharmacology & Therapeutics, January 2017, Wiley

    Aisha Elsharkawy